


**NEW
UPDATE**

Lupin receives milestone payment of \$ 50mn for achieving clinical development milestone of LNP3794.



Agreement value more than \$700mn



MEK inhibitor (LNP3794; BI 3011441) is a small-molecule allosteric inhibitor that binds adjacent to the ATP pocket of MEK, resulting in inhibition of MEK kinase activity. LNP 3794 an inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK), a key component of the RAS/RAF/MEK/ERK signaling pathway.

ERK, extracellular signal-regulated kinase; GDP, guanosine diphosphate; GTP, guanosine triphosphate; KRAS, Kirsten rat sarcoma; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated extracellular signal-regulated kinase; P, phosphate.

MEK inhibitor (LNP3794; BI 3011441) + KRAS inhibitor (BI 1701963)- complementary mechanisms of action for gastrointestinal and lung cancer

Country	Phase	No of Participants	Clinical Study Identifier	Sponsor	Details
India	II/ III	141	CTRI/2017/12/010781 - Terminated	Lupin	8mg (Soft Gelatin Capsules) of 2mg strength
India	II	30	CTRI/2019/01/017245	Lupin	LNP3794, 8 mg (4 capsules each of 2 mg), once daily, per oral till end of treatment / early discontinuation - refractory type of Lung cancer which has RAS mutations for which no treatment exists worldwide.
Europe	I	17	IRAS ID 157025 - Completed	Lupin	Terminally-ill patients (Lung Cancer, Melanoma & Colon Cancer)
Japan	I	124	NCT04835714	Boehringer Ingelheim	BI 1701963 Alone and in Combination With BI 301144
Japan	I	12	NCT04742556	Boehringer Ingelheim	BI 3011441 Monotherapy